Factors That Effect the Gait Speed in Diabetic Individuals Without Neuropathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

71 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-20

Study Completion Date

2021-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study planned to investigate the role of potential explanatory factors effecting the speed of gait such as muscle mass, aerobic capacity, physical activity status, cognitive function, blood pressure, and metabolic measures considering age, sex, and education years in diabetic individuals without neuropathy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Balance and Gait in Diabetic Neuropathy

NCT05127538

Neuropathy, Diabetic Pain, Neuropathic Gait Disorder, Sensorimotor

COMPLETED NA

Postural Control, Ankle and Trunk Proprioception in Type 2 Diabetes

NCT06045598

Type2diabetes

UNKNOWN

Effect of Sensory Training on Functional Performance, Balance, Gait in Type 2 Diabetic Individuals With Neuropathy

NCT06979401

Diabetes Type 2 Diabetes Diabetic Peripheral Neuropathy +5 more

NOT_YET_RECRUITING NA

Effects of Modified Otago Exercises in Individuals With Diabetic Neuropathy

NCT05691738

Diabetes Mellitus, Type 2 Neuropathy

COMPLETED NA

The Effect of Foot and Ankle Exercise on Pain and Quality of Life in Patients With Diabetic Neuropathy

NCT05670600

Diabetic Neuropathy, Painful

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Type 2 diabetic people will be screened by clinical symptoms of neuropathy and DN4 questionnaire. Among those who did not have neuropathic symptoms or who have DN4 score below 4 will be considered for the study.Then aerobic capacity will be measured by a cycle ergometer and VO2max will be obtained. Weight, body mass index and muscle mass will be measured by bioimpedance analysis. Physical activity status will be determined by International Physical Activity Score (IPAQ). Cognitive function will be evaluated by Mini Mental test. HbA1c and fasting blood glucose will be measured in venous blood after overnight fasting. Blood pressure will be measured in the sitting position after resting from the left arm. Speed of gait will be measured by an accelerometer.Then, the effect of above mentioned factors on speed of gait will be studied.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gait Disorder, Sensorimotor Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

measurement of gait speed

Cross sectional, cohort

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

measurement of aerobic capacity measurement of muscle mass measurement of blood glucose and HbA1c cognitive function testing physical activity questioning blood pressure measurement

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals with Diabetes Mellitus less than 10 years but longer than 1 year
* Absence of neuropathic symptoms
* DN4 questionnaire sore less than 4

Exclusion Criteria

Individuals who had

* insulin therapy,
* poor glycemic control,
* manifesting cardiovascular disease,
* retinopathy or other visual problems,
* diabetic neuropathy,
* nephropathy,
* cerebrovascular disease,
* cognitive impairment,
* heart failure,
* alcohol or cigarette dependence,
* cancer,
* chemo/radiotherapy,
* foot ulcer,
* orthopedical or surgical problems
* wheel-chair or any assistive devices for ambulation
* prominent knee or hip arthritis, prosthesis

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No